59441-32-6

Basic information

• Product Name: 1-(1-Oxohexadecyl)-L-proline
• Synonyms: N-HEXADECANOYL-PROLINE;1-(1-oxohexadecyl)-L-proline;PALMITOYL PROLINE;L-Proline,1-(1-oxohexadecyl)-;1-Hexadecanoylpyrrolidine-2-carboxylic acid;1-Palmitoyl-L-proline;1-Palmitoylproline;Einecs 261-763-5
• CAS NO: 59441-32-6
• Molecular Formula: C₂₁H₃₉NO₃
• Molecular Weight: 353.54
• EINECS: 261-763-5
• Mol File: 59441-32-6.mol
• Article Data: 10

Chemical Properties

• Melting Point: 66-67 °C
• Boiling Point: 511.6 °C at 760 mmHg
• Flash Point: 263.2 °C
• Appearance: /
• Density: 0.997 g/cm³
• Vapor Pressure: 7.58E-12mmHg at 25°C
• Refractive Index: 1.488
• PKA: 3.69±0.20(Predicted)
• CAS DataBase Reference: 1-(1-Oxohexadecyl)-L-proline(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-Oxohexadecyl)-L-proline(59441-32-6)
• EPA Substance Registry System: 1-(1-Oxohexadecyl)-L-proline(59441-32-6)

Safety Data

• Hazardous Substances Data: 59441-32-6(Hazardous Substances Data)

Usage

General Description

1-(1-Oxohexadecyl)-L-proline is a chemical compound that belongs to the class of organic compounds known as proline and derivatives. It is a derivative of the amino acid proline, containing an additional hexadecyl group attached to the nitrogen atom. 1-(1-Oxohexadecyl)-L-proline is used in the synthesis of peptides and proteins, and it has potential applications in the pharmaceutical industry for drug development. It may also have potential biological activities, particularly in the modulation of enzyme functions and as a potential therapeutic agent for various diseases. Additionally, it has been studied for its potential role in lipid metabolism and as a precursor for the synthesis of other bioactive compounds.

InChI:InChI=1/C21H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-17-20(23)22-18-15-16-19(22)21(24)25/h19H,2-18H2,1H3,(H,24,25)

Upstream product

• 147-85-3 L-proline 
• 112-67-4 n-hexadecanoyl chloride 
• 57-10-3 1-hexadecylcarboxylic acid 
• 81912-43-8 rac.-3-hexadecanoyl-4-methoxycarbonyl-1,3-thiazolidine-2-thione 
• 14464-31-4 palmitic acid N-succinimide ester 

Relevant articles and documents

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AT LEAST ONE IONIC SPECIES AND AN AMPHOIPHILIC COMPOUNDS CONTAINING HYDRIPHOBIC RADICALS

A composition in the form of an injectable solution includes: amylin, an amylin receptor agonist or an amylin analog; at least one ionic species; and an amphiphilic compound having a hydrophilic skeleton HB, substituted by at least one hydrophobic radical -Hy according to formula (I). A composition further is characterised in that it also has prandial insulin. In one embodiment, the composition also has GLP-1, GLP-1 analogs, and GLP-1 receptor agonists, commonly called GLP-1 RA.

HUMAN MICROBIOTA DERIVED N-ACYL AMIDES FOR THE TREATMENT OF HUMAN DISEASE

The present invention provides compositions and methods for the modulation of G protein-coupled receptors (GPCRs). The invention provides a genetically engineered cell, wherein the cell expresses a human microbial N-acyl synthase (hm-NAS) gene. In one embodiment, the hm-NAS gene is N-acyl serinol synthase. The invention provides a probiotic composition, the probiotic composition comprises a genetically engineered cell of the invention. The invention provides a method for modulating a G protein-coupled receptor (GPCR) activity in a subject, the method comprises administering to the subject an effective amount of a composition comprising at least one selected from the group consisting of a genetically engineered cell, an hm-NAS gene, and a N-acyl amide.

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOG, AND A CO-POLYAMINO ACID

An injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: [in-line-formulae]?GpR?r?GpA?a?GpC)p ??I[/in-line-formulae] wherein the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition wherein it moreover comprises a prandial insulin.